n°151

July 2014

Issue Contents
Editorial

Free  Precaution(s)

p.172
Taking sufficient time to evaluate innovations

Marketing Authorisations

Peglotigase (New Drug)

p.173-176
An excessively dangerous and inadequately evaluated hypouricaemic drug

INN common stem: -ampanel

p.176

Bosutinib (New Drug)

p.177
Chronic myeloid leukaemia in treatment failure: major toxicity

Free  Canakinumab for gout attacks (New Indication)

p.178
Too risky

Perampanel (New Drug)

p.179
Just another anticonvulsant for partial epilepsy: no progress

Adverse Effects

Drug-induced nail disorders

p.180-182
Mainly cytotoxic and photosensitising drugs

Ethinylestradiol + cyproterone: back in France for acne and hirsutism, despite frequent off-label prescription

p.183
Unjustified risk of thromboembolism

Intravenous iron-containing products: EMA procrastination

p.184-185
Keeping iron dextran on the European market is absurd

An aberrant decision by the European authorities to keep iron dextran on the market

p.185
Editor's opinion

Dabigatran: gastrointestinal ulcers

p.186
Risk of serious bleeding

SSRI antidepressants: postpartum haemorrhage

p.186
A cohort study

Reviews

Head lice

p.187-190
Dimeticone is the pediculicide of choice

Vitamins and minerals: no preventive effect against cardiovascular disease

p.191
The Physician's Health study

Acute rhinosinusitis: no tangible benefit with antibiotic therapy

p.191
Amoxicillin does not speed recovery

Outlook

Controlling and monitoring exposure to radiation from medical imaging

p.192-195
Changing perceptions of radiological risks

Free  "Partnership" or manipulation?

p.195
Partnering with industry is not a trivial matter

Masthead

Free  Masthead

p.170

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe